Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Shares of Hims & Hers Health (HIMS) are getting crushed today after the Food & Drug Administration determined there is no ...

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.

The FDA just slammed the door on its booming weight-loss drug business--but Hims & Hers has a bold new strategy.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.